Meso Scale Diagnostics CEO Prompts BioVeris Nasdaq Delistment
This article was originally published in The Gray Sheet
Executive Summary
BioVeris will file a request by August for a Nasdaq Listing Qualifications Panel to review a staff determination and stay the firm's stock delistment